Navigation Links
ThromboGenics NV Announces Business Update and Half Year Results 2009
Date:8/27/2009

,393 - 62,393 Net result 2009 (4,663) (4,663) (4,663) Conversion of warrants by 2,783 2,783 ThromboGenics Ltd Contribution in kind Thrombogenics Ltd shares 2,783 (2,783) Conversion of warrants by ThromboGenics NV 241 241 Exchange rate differences as a result of retranslation of foreign subsidiary 11 11 Share based payments 249 249 Fair-Value Adjustment Investments 72 72 Balance sheet at 30 Jun 2009 (48,622) 61,086 - 61,086

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels unde
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... of chronic pain, announced the results of its annual ... was a transformational year in Relmada,s history and it ... company," said Sergio Traversa , chief executive officer ... on key financial, human resource and clinical development objectives ...
(Date:12/17/2014)... Houston, TX (PRWEB) December 17, 2014 ... marketing and administration for Stoller Group. In this position, ... Stoller Group, on administrative matters, develop marketing strategy and ... and services. , “Achim has tremendous knowledge and ... president of Stoller Group. “His experience and innovative thinking ...
(Date:12/17/2014)... Xeno Diagnostics has again received an ... COLA inspection. Xeno has met all criteria for ... organization. Accreditation is earned only by laboratories that ... demonstrate continued accuracy in the performance of proficiency ... , While the Laboratory Excellence award ...
(Date:12/17/2014)... Md. , Dec. 17, 2014  United Therapeutics ... senior executive promotions as well as changes to ... Senior Executive Promotions United Therapeutics announced ... President and Co-Chief Executive Officer and David Zaccardelli ... Officer.  In connection with these promotions, Dr. Rothblatt,s title ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4
... Engineering Technology to Bring New Choices, More Options to Global ... ... and RESEARCH TRIANGLE PARK, N.C., Feb. 11,/PRNewswire- FirstCall/ -- DuPont (NYSE: ... to bring higher-yielding,agricultural products to the market faster. Terms of the ...
... 11 On February 8, Michael F. Brigham,President ... ) (http://www.immucell.com ),updated the investment community in ... in the interview include an overview of the,company, ... for,which investors should watch., To hear the ...
... to gently clean and help heal ... ... today,announced that it has launched the Qoustic Wound Therapy System(TM), which,advances ... a safe, cost-effective alternative to painful sharps,debridement and other surgical modalities. ...
Cached Biology Technology:DuPont and Precision BioSciences Collaborate to Accelerate Crop Product Development 2WallSt.net Updates Investment Community Through All-New Interview With ImmuCell 2Arobella Medical, LLC Launches Qoustic Wound Therapy System(TM) 2Arobella Medical, LLC Launches Qoustic Wound Therapy System(TM) 3
(Date:12/3/2014)... Dec. 2, 2014 As part of our ... Technologies is pleased to announce the release of a ... to collect the workforce data that they need. ... been left by existing readers. Many such devices have ... and modern technology. Older models force users to navigate ...
(Date:11/21/2014)... 2014   Atmel® Corporation (NASDAQ: ... touch technology solutions, today launched the industry,s first family ... widest V cc range from 1.7V to 5.5V. ... I 2 C bus communication speeds, and are available ... them ideal for consumer, industrial, computer, and medical applications. ...
(Date:11/15/2014)... 13, 2014  While we may still be a few ... in "Star Trek" to gain instant access to all that ... with smartphones and tablets for monitoring and measuring our health ... This may seem a tad Orwellian to some, but a ... of these technological opportunities into their healthcare regime. ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... Education for All) argues that the education of children ... and nutrition, which have reduced major diseases in poor ... Matthew Jukes, one of the books authors says: ... in schools, wed go a long way to enabling ...
... M2SYS Fingerprint Technology to ... Accurately Verify Check Casher Identity, ATLANTA, Sept. ... development firm, announced today its partnership,with TeraCorp Enterprises, a ... the M2SYS Bio-Plugin(TM) fingerprint,solution into TeraCash, a cutting-edge check ...
... the latest horticulture research on high tunnels, ... The American Society for Horticultural Science (ASHS) ... horticulture presentations from the 2007 ASHS Annual ... broad selection of horticulture presentations by world-class ...
Cached Biology News:Leading experts cite poor health and nutrition as major barrier to education in developing world 2M2SYS Technology Partners with TeraCorp Enterprises to Provide Added Security Within Check Cashing Solution 2HortTalks, a valuable scientific resource 2
... tool provides the firm pressure necessary ... in tubes or plates. The multifunctional ... that firmly holds thin-wall 0.5 ml ... opening or closing. A side slot ...
... USP is a highly nutritious versatile medium ... Due to the inclusion of both Tryptone ... growth of many fastidious organisms without the ... to United States Pharmacopeia standards for use ...
...
... B-Bridge's siSolutions RNAi Services offer ... for your siRNA studies. B-Bridges advanced ... and technical expertise ensure that you ... experiments. siSolutions siRNA Design Service utilizes ...
Biology Products: